Inceptionr LLC Invests $839,000 in STERIS plc $STE

Inceptionr LLC acquired a new stake in STERIS plc (NYSE:STE) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,792 shares of the medical equipment provider’s stock, valued at approximately $839,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Activest Wealth Management lifted its stake in STERIS by 423.8% during the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 89 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in STERIS in the fourth quarter valued at approximately $28,000. Cornerstone Planning Group LLC increased its stake in STERIS by 342.3% in the fourth quarter. Cornerstone Planning Group LLC now owns 115 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 89 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 104 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in STERIS in the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Transactions at STERIS

In other news, Director Richard C. Breeden sold 1,481 shares of STERIS stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total value of $310,284.31. Following the transaction, the director directly owned 38,964 shares of the company’s stock, valued at $8,163,347.64. The trade was a 3.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP John Adam Zangerle sold 1,419 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $209.28, for a total transaction of $296,968.32. Following the completion of the sale, the vice president owned 35,259 shares of the company’s stock, valued at approximately $7,379,003.52. This trade represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 7,328 shares of company stock worth $1,554,051. Insiders own 1.12% of the company’s stock.

STERIS Stock Up 1.7%

Shares of NYSE STE opened at $214.16 on Friday. The stock has a market cap of $20.87 billion, a PE ratio of 27.01 and a beta of 0.92. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44. The business has a 50-day moving average price of $211.69 and a 200 day moving average price of $227.60.

STERIS (NYSE:STE) last released its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the firm earned $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities research analysts forecast that STERIS plc will post 11.18 earnings per share for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 26th. Stockholders of record on Monday, June 8th were given a dividend of $0.63 per share. The ex-dividend date was Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. STERIS’s dividend payout ratio (DPR) is 31.78%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $270.00 target price on shares of STERIS in a research report on Thursday, May 21st. Finally, KeyCorp cut their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.